ReviewArchives of medical research2021
Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
Review in Archives of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Effect of COVID-19 vaccination on the outcome ofFrontiers in public health · 2023Pooled it
- Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: A comprehensive systematic review.Journal of medical virology · 2022Pooled it
- Effect of the COVID-19 Pandemic on Serum Vitamin D Levels in People Under Age 18 Years: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Potential ofBioMed research international · 2022Pooled it
- Pooled it
- The top 100 most cited articles on COVID-19 vaccine: a bibliometric analysis.Clinical and experimental medicine · 2023Trial
- Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.Clinics (Sao Paulo, Brazil) · 2023Trial
- Modelling Hollow Microneedle-Mediated Drug Delivery in Skin Considering Drug Binding.Pharmaceutics · 2025Article
- The impact of inoculation with the inactivated COVID-19 vaccine on the outcomes ofFrontiers in endocrinology · 2025Article
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- A deep learning drug screening framework for integrating local-global characteristics: A novel attempt for limited data.Heliyon · 2024Article
- Article
- Precise modulation and use of reactive oxygen species for immunotherapy.Science advances · 2024Review
- Cryogels and Monoliths: Promising Tools for Chromatographic Purification of Nucleic Acids.Gels (Basel, Switzerland) · 2024Review
- Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.Current research in microbial sciences · 2024Review
- Evaluations of FDA-approved Drugs Targeting 3CLP of SARS-CoV-2 Employing a Repurposing Strategy.Combinatorial chemistry & high throughput screening · 2024Article
- A Multi-Machine Learning Consensus Model Based on Clinical Features Reveals That Interleukin-10 Derived from Monocytes Leads to a Poor Prognosis in Patients with Coronavirus Disease-2019.Journal of inflammation research · 2024Article
- SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case-Control Study.Vaccines · 2023Article
- The role of SARS-COV-2 infection in promoting abnormal immune response and sepsis: A comparison between SARS-COV-2-related sepsis and sepsis from other causes.Infectious medicine · 2023Article
- Membrane-Active Peptides and Their Potential Biomedical Application.Pharmaceutics · 2023Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus disease 2019 (COVID-19) pandemic has spread to almost all nooks and corners of the world. There are numerous potential approaches to pharmacologically fight COVID-19: small-molecule drugs, interferon therapies, vaccines, oligonucleotides, peptides, and monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being used for the identification of B cell and cytotoxic T lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or β-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are being designed and moved into clinical trials, these types of vaccines are yet to be approved by regulatory bodies for human use. This review focuses on the drugs and vaccines being developed against the COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.